IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

PRIMARY OBJECTIVES:

I. To compare the proportion of subjects who achieve a pathologic complete response (CR) or
partial response (PR) in regimen 1 versus regimen 2 at week 25, based on the resected
surgical specimen.

SECONDARY OBJECTIVES:

I. To evaluate the toxicity and feasibility of administration of IRX-2 in subjects with
confirmed cervical intraepithelial neoplasia (CIN) 3 or vulvar intraepithelial neoplasia
(VIN) 3.

II. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: the occurrence of clinical CRs or PRs at weeks 6, 13 and 25.

III. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: frequency of elimination of human papillomavirus (HPV) in
cervical or vulvar tissue using a commercial HPV genotyping assay and viral load
determination by quantitative polymerase chain reaction (PCR).

IV. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: analysis of the immune infiltrates in the resected surgical
specimens.

V. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: immunophenotypic analysis of peripheral blood lymphocytes.

VI. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: frequency of serum antibodies to HPV E6, E7 and L1 proteins by
enzyme-linked immunosorbent assay (ELISA).

VII. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the
treatment of CIN 3 or VIN 3: ribonucleic acid (RNA) expression profiling of
immune-inflammatory markers from post-treatment resected surgical specimens.

OUTLINE: Patients are randomized to 1 of 2 arms.

Arm I: Patients receive cyclophosphamide intravenously (IV) on day 1 and IRX-2 via submucosal
injections in the cervix or subcutaneously (SC) for vulvar lesions on days 4-7. Patients also
receive indomethacin orally (PO) three times daily (TID), zinc-containing multivitamins (PO)
once daily (QD) and omeprazole orally (PO) on days 1-21.

Arm II: Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections
in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO
TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21.

In both arms, treatment repeats every 6 weeks for up to 2 courses in the absence of disease
progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.

After completion of study treatment, patients are followed up at 1-8 weeks after surgery.

Inclusion Criteria:

- Histologically confirmed squamous CIN 3, or VIN 3 (usual type only)

- The subject is either surgically sterile, postmenopausal, or agrees to practice an
effective method of birth control as determined by the investigator (to be continued
throughout the study period), except that subjects with CIN 3 are not permitted to use
a cervical cap or diaphragm for contraception

- White blood cell > 2,500/ mcL (> 2.5 x 10^9/L)

- Absolute neutrophil count > 1,000/ microliter (> 1 x 10^9/L)

- Platelet count > 75,000/ mcL (> 75 x 10^9/L)

- Hemoglobin >= 8 g/dL (>= 80 g/L) (subjects who have received a transfusion or
erythropoietin up to one week prior to receiving the first dose of cyclophosphamide
are eligible for the study)

- International normalized ration (INR) or prothrombin time (PT) < 1.5 x ULN (upper
limit of normal)

- Activated partial thromboplastin time (aPTT) < 1.5 x ULN

- Serum creatinine < 1.5 x ULN

- Total bilirubin < 2.0 x ULN unless thought to be related to inherited bilirubin
conjugation disorder (ie Gilbert?s disease)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN

- The subject is geographically accessible for ongoing follow-up and is committed to
comply with the designated visits

- The subject is capable of understanding and complying with the protocol and has signed
the enrollment informed consent form at screening

Exclusion Criteria:

- For subjects with cervical dysplasia: evidence of atypical glandular cells or
adenocarcinoma in situ (ACIS) based on cervical cytology, colposcopy or biopsy

- For subjects with either cervical or vulvar squamous dysplasia: evidence of
microinvasive squamous carcinoma based on cytology, colposcopy or biopsy

- Pregnancy or lactation

- Allergy to ciprofloxacin or other quinolones (because ciprofloxacin is used in
preparation of IRX-2)

- Allergy to indomethacin (a necessary component of the regimen) or to acetylsalicylic
acid (aspirin) due to likely allergy cross-reaction

- Aldara (imiquimod) for the topical treatment of lower genital tract warts or dysplasia
within 3 months of study enrollment

- Known to be positive for human immunodeficiency virus-1 (HIV-1) antibody, human
immunodeficiency virus-2 (HIV-2) antibody, hepatitis B surface antigen, or hepatitis C
virus antibody

- Known to have other immunodeficiency diseases, including cellular immunodeficiencies,
hypogammaglobulinemia, or dysgammaglobulinemia

- Immunotherapy (eg, interferons, tumor necrosis factor, interleukins) or biological
response modifiers (granulocyte-macrophage colony-stimulating factor, granulocyte
colony-stimulating factor, macrophage colony-stimulating factor) or any
investigational drug within 3 months of study enrollment

- Concurrent treatment with systemic corticosteroids at a dose of >= 5 mg/day of
prednisone (or equivalent)

- Subjects should not take aspirin (except for low-dose aspirin as prescribed for
vascular disease) or other non-prescribed, non-steroidal anti-inflammatory agents from
randomization to surgery

- An infectious process or any other significant illness such as an autoimmune disease
or advanced age that in the opinion of the investigator would compromise the subject?s
ability to mount an immune response

- Impaired hepatic, renal or hematological function, evidenced by:

- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total
bilirubin >= 2 times upper limit of normal (ULN),

- Serum creatinine >= 2 times ULN, or

- Clinically significant active cardiovascular disease, including a history of
myocardial infarction within the past 6 months, heart failure as defined by New York
Heart Association classes III or IV, and/or blood pressure greater than 160/90 mm Hg
(1 repeat measure allowed no more than 5 minutes after the first measurement)

- History of severe allergic reaction to insect bites or stings, or to any biologic
pharmaceutical product, including compounds similar to the test article

- Any medical contraindications, allergies or previous therapy that would preclude
treatment with the components of the IRX-2 regimen, i.e., cyclophosphamide,
indomethacin, zinc-containing multivitamins or omeprazole

- Donation or loss of > 450 mL of blood or plasma within 30 days of randomization